16.02.2024 10:00:03
|
EQS-News: Sartorius releases Annual Report for 2023
EQS-News: Sartorius AG
/ Key word(s): Annual Report
Göttingen, February 16, 2024
Sartorius releases Annual Report for 2023 The life science group Sartorius has released its Annual Report for 2023 today. The document is available under the following link: https://ir-reports.sartorius.com/en/ag/fy-2023. Financial calendar March 28, 2024 Annual General Meeting April 18, 2024 Publication of first-quarter figures (January to March 2024) July 19, 2024 Publication of first-half figures (January to June 2024) October 17, 2024 Publication of nine-month figures (January to September 2024) A profile of Sartorius Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers around the globe. Contact Timo Lindemann External Communications +49 (0)551.308.4724 timo.lindemann@sartorius.com Follow Sartorius on LinkedIn. Additional features: File: Press Release
16.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | SARTORIUS AG |
Otto-Brenner-Straße 20 | |
37079 Göttingen | |
Germany | |
Phone: | +49.(0)551-308.0 |
Fax: | +49.(0)551-308.3289 |
E-mail: | info@sartorius.com |
Internet: | www.sartorius.com |
ISIN: | DE0007165607, DE0007165631 |
WKN: | 716560 , 716563 |
Indices: | DAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1838357 |
End of News | EQS News Service |
|
1838357 16.02.2024 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sartorius AG St.mehr Nachrichten
06.12.24 |
Sartorius bestellt Michael Grosse ab Juli 2025 zum CEO (Dow Jones) | |
17.10.24 |
Pharmazulieferer: „Wir sind auf Kurs“- Sartorius sieht stabilisierendes Geschäft (Handelsblatt) | |
16.10.24 |
Ausblick: Sartorius gewährt Anlegern Blick in die Bücher (finanzen.net) | |
02.10.24 |
Erste Schätzungen: Sartorius veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
19.07.24 |
Sartorius-Aktie fällt zweistellig: Ausblick für 2024 nach unten revidiert (finanzen.at) | |
19.07.24 |
Dax-Konzern: Schwaches erstes Halbjahr - Sartorius kappt seine Jahresziele (Handelsblatt) | |
19.07.24 |
Gewinnwarnung : Sartorius kappt seine Jahresziele - Aktie rund 15 Prozent im Minus (Handelsblatt) | |
18.07.24 |
NACHBÖRSE/XDAX -0,2% auf 18.321 Pkt - Sartorius mit gesenktem Ausblick im Minus (Dow Jones) |